ADVL1622: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases in Children and Young Adults with Refractory Sarcomas Wilms Tumor and Other Rare Tumors

Brief description of study

If you or your child have been diagnosed with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors, you may qualify to participate in this study evaluating the experimental drug XL184 (Cabozantinib). The main goal of this phase II study is to see what effects, good and/or bad, a drug or combination of drugs has on people with a type of cancer.

Clinical Study Identifier: s17-00815 Identifier: NCT02867592
Principal Investigator: Sharon L Gardner
Currently Recruiting

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.